Business Context and Reporting Period
This Form 8-K is a current report filed by Stellar Biotechnologies, Inc. (not Edesa Biotech, Inc.) on May 16, 2018. The registrant is incorporated in British Columbia, Canada, with principal executive offices in Port Hueneme, California. The filing addresses Item 8.01 (Other Events) regarding a specific update to the company's capital structure.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only quantitative metric disclosed is the share count:
- Total Common Shares Issued and Outstanding: 3,196,266 as of May 16, 2018.
- Shares from Pre-funded Warrants: 305,000 shares included in the total count, resulting from the exercise of pre-funded warrants issued during a best efforts public offering of units and pre-funded units.
Material Changes
The material change reported is the increase in outstanding common shares due to the exercise of 305,000 pre-funded warrants. This event was part of a public offering previously disclosed in a Form 8-K filed on May 15, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a purely informational report regarding share count updates.
Investor Verification Checklist
- Verify the correct registrant name is Stellar Biotechnologies, Inc., as the input metadata incorrectly referenced Edesa Biotech, Inc.
- Confirm the total share count of 3,196,266 reflects the inclusion of the 305,000 shares from the warrant exercise.
- Review the Form 8-K filed on May 15, 2018, for details regarding the best efforts public offering of units and pre-funded units.